Xeris Biopharma Holdings (XERS) Debt to Equity (2023 - 2025)
Historic Debt to Equity for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q3 2025 value amounting to -$254.9.
- Xeris Biopharma Holdings' Debt to Equity fell 4784803.74% to -$254.9 in Q3 2025 from the same period last year, while for Sep 2025 it was -$254.9, marking a year-over-year decrease of 4784803.74%. This contributed to the annual value of -$7.84 for FY2024, which is 7469.35% up from last year.
- According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Debt to Equity is -$254.9, which was down 4784803.74% from -$11.33 recorded in Q2 2025.
- Xeris Biopharma Holdings' 5-year Debt to Equity high stood at $4.53 for Q3 2023, and its period low was -$254.9 during Q3 2025.
- Moreover, its 3-year median value for Debt to Equity was -$0.53 (2024), whereas its average is -$27.82.
- Its Debt to Equity has fluctuated over the past 5 years, first surged by 7469.35% in 2024, then tumbled by 5190527.2% in 2025.
- Over the past 3 years, Xeris Biopharma Holdings' Debt to Equity (Quarter) stood at -$30.97 in 2023, then soared by 74.69% to -$7.84 in 2024, then plummeted by 3152.31% to -$254.9 in 2025.
- Its Debt to Equity was -$254.9 in Q3 2025, compared to -$11.33 in Q2 2025 and -$6.54 in Q1 2025.